Immunome Inc: amends license agreement with Bristol-Myers Squibb

What happened

• The filing says Immunome, Inc. entered into Amendment No. 4 to the license agreement with Bristol-Myers Squibb Company on Oct 2, 2026. The Amendment removes Immunome’s obligation to make any milestone and royalty payments under the license agreement and assigns to Immunome patent rights related to varegacestat and AL101 that were previously licensed to Immunome.
• As consideration for the Amendment, the filing says Immunome paid Bristol-Myers Squibb $20,000,000 in cash and issued 4,425,487 shares of its common stock. The filing also says Immunome and Bristol-Myers Squibb entered into a stock issuance agreement concurrently with the Amendment under which the 4,425,487 shares were issued and Immunome agreed to seek registration of the shares for resale.

Key details

• Date of Amendment: Oct 2, 2026.
• Consideration: $20,000,000 cash and 4,425,487 shares of common stock.
• Amendment effects: removes milestone, royalty and other payment obligations to Bristol-Myers Squibb and assigns patent rights related to varegacestat (formerly AL102) and AL101 to Immunome.
• Resale registration: Immunome agreed to use commercially reasonable efforts to file a resale registration statement for the shares with the SEC by Nov 16, 2026 and to cause it to be declared effective as soon as practicable, but no later than 60 calendar days after filing (or within 5 business days after notice the SEC will not review further). The filing also notes indemnity and expense provisions in the stock issuance agreement.

Why it may matter

• The filing reports Item 1.01 (entry into a material definitive agreement) describing the Amendment to the license agreement and the related stock issuance, and Item 3.02 (unregistered sale of equity securities) noting the shares were issued pursuant to Section 4(a)(2) of the Securities Act and are not registered. The filing does not show why the insider traded or why the company acted.